Platform oncolytic vector for systemic delivery
AssigneeKaliVir Immunotherapeutics, Inc.
InventorsStephen H. THORNE, Daniel J. BYRD, Mingrui ZHANG
Life of this patent
Estimating the term…
Abstract
This disclosure provides a modified oncolytic virus that can contain modifications in the viral genome and exogenous nucleic acids coding for proteins. The modified oncolytic virus can be utilized as a platform vector for systemic delivery.
Claims27
-206. (canceled)
An oncolytic virus comprising a mutation or a deletion or a partial deletion of the viral gene K7R, and further comprising at least one of:
- (a) an exogenous nucleic acid that codes for a cytokine, or a functional domain or a fragment or a variant thereof;
- (b) an exogenous nucleic acid that codes for a cytokine receptor, or a functional domain or a fragment or a variant thereof;
- (c) an exogenous nucleic acid that codes for a chemokine, or a functional domain, or a fragment or a variant thereof;
- or
- (d) any combination of (a)-(c).
An oncolytic virus comprising an exogenous nucleic acid that codes for IL15 and IL15-Rα, or a functional domain or a fragment or a variant thereof.
An oncolytic virus comprises an exogenous nucleic acid that codes for IL15 and IL15-Rα, or a functional domain or a fragment or a variant thereof, wherein the virus further comprises a mutation or a deletion or a partial deletion of the viral gene K7R.
Dependencies are inferred from the claim text.